Abacus Wealth Partners LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN

Abacus Wealth Partners LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 1,140 shares of the biopharmaceutical company’s stock, valued at approximately $880,000.

Several other institutional investors and hedge funds also recently made changes to their positions in REGN. Leuthold Group LLC lifted its position in shares of Regeneron Pharmaceuticals by 56.2% in the fourth quarter. Leuthold Group LLC now owns 9,439 shares of the biopharmaceutical company’s stock worth $7,286,000 after purchasing an additional 3,395 shares in the last quarter. L & S Advisors Inc bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $3,592,000. Soltis Investment Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals by 39.3% in the fourth quarter. Soltis Investment Advisors LLC now owns 862 shares of the biopharmaceutical company’s stock worth $665,000 after purchasing an additional 243 shares in the last quarter. ARS Investment Partners LLC lifted its position in shares of Regeneron Pharmaceuticals by 23.2% in the fourth quarter. ARS Investment Partners LLC now owns 35,445 shares of the biopharmaceutical company’s stock worth $27,359,000 after purchasing an additional 6,676 shares in the last quarter. Finally, iA Global Asset Management Inc. lifted its position in shares of Regeneron Pharmaceuticals by 3.8% in the fourth quarter. iA Global Asset Management Inc. now owns 21,014 shares of the biopharmaceutical company’s stock worth $16,220,000 after purchasing an additional 766 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on REGN shares. Oppenheimer reissued an “outperform” rating and issued a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. JPMorgan Chase & Co. boosted their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Zacks Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Sanford C. Bernstein dropped their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Finally, Royal Bank Of Canada dropped their price target on shares of Regeneron Pharmaceuticals from $779.00 to $762.00 and set a “sector perform” rating on the stock in a research report on Thursday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $826.59.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $698.25 on Friday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The firm’s fifty day moving average price is $744.69 and its two-hundred day moving average price is $744.97. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The firm has a market capitalization of $73.82 billion, a P/E ratio of 17.01, a price-to-earnings-growth ratio of 1.55 and a beta of 0.30.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s revenue was up 19.0% on a year-over-year basis. During the same period in the prior year, the firm earned $8.22 earnings per share. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.1 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be given a $0.94 dividend. The ex-dividend date of this dividend is Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.